...
首页> 外文期刊>Oncoimmunology. >PD-L1 regulation by SDH5 via P-catenin/ZEB1 signaling
【24h】

PD-L1 regulation by SDH5 via P-catenin/ZEB1 signaling

机译:PD-L1通过P-Catenin / Zeb1信号传导的SDH5调节

获取原文
获取原文并翻译 | 示例
           

摘要

Programmed death-ligand 1 (PD-L1) is a crucial target for lung cancer immunotherapy. In lung cancer patients with high PD-L1 expression, blocking or reducing its expression can inhibit tumor growth. PD-L1 is regulated by signaling pathways, transcription factors and epigenetic factors, such as the GSK3β/β-catenin pathway, P53 protein and EMT. In our previous study, succinate dehydrogenase 5 {SDH5) was reported to regulate ZEB1 expression, induce EMT and lead to lung cancer metastasis via the GSK3β/β-catenin pathway. It is possible that SDH5 is involved in the mechanisms of PD-L1 regulation. In the present study, we observed a negative correlation between the expression of PD-L1 and SDH5 in vivo and in vitro. The examination of patient tissues also confirmed our results. Furthermore, we also found that SDH5 could reverse PD-L1 expression by the GSK3β/β-catenin/ZEB1 pathways. All these results reveal that SDH5 regulates PD-L1 expression and suggest that SDH5 can be used as a marker to predict tumor immune micro-states and provide guidance for clinical immunotherapy.
机译:编程死亡 - 配体1(PD-L1)是肺癌免疫疗法的关键目标。在具有高PD-L1表达的肺癌患者中,阻断或降低其表达可以抑制肿瘤生长。 PD-L1通过信号通路,转录因子和表观遗传因子来调节,例如GSK3β/β-Catenin途径,P53蛋白和EMT。在我们以前的研究中,据报道琥珀酸脱氢酶5 {SDH5)调节Zeb1表达,诱导EMT并通过GSK3β/β-Catenin途径导致肺癌转移。 SDH5可以参与PD-L1调节的机制。在本研究中,我们观察到PD-L1和SDH5在体内和体外表达之间的负相关性。检查患者组织还证实了我们的结果。此外,我们还发现SDH5可以通过GSK3β/β-catenin / Zeb1途径反转PD-L1表达。所有这些结果表明,SDH5调节PD-L1表达,并表明SDH5可用作预测肿瘤免疫微态的标记,并为临床免疫疗法提供指导。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号